CoreMap Secures $35.5M for AF Mapping Study

CoreMap has added substantial equity capital while advancing an investigational system designed to map persistent atrial fibrillation with greater precision. A June 24, 2026 SEC filing reports that the Burlington, Massachusetts medical-device company sold $35.51M in equity toward a $45M offering.

That public record matters because the original intake headline described a $37M Series C. The filing does not use the Series C label, identify the current investors, or disclose a valuation, so the verified story is narrower and more useful: CoreMap has raised $35.51M in new equity while its clinical program moves through a consequential stage.

The capital arrives as CoreMap advances INvENI, a global, multi-site feasibility study of its electrophysiology mapping system in persistent and long-standing persistent atrial fibrillation. The broader market signal is not that money has solved the science. It is that investors have financed more time for the science to prove itself.

What Happened

CoreMap's Form D lists a $45M equity offering, $35,509,826 sold, and $9,490,174 remaining as of the filing. The first sale occurred on June 18, 2026, and 73 accredited investors had participated. The filing does not disclose lead investors, participating firms, revenue, valuation, or the intended use of proceeds.

That distinction is worth keeping clear. Private-market headlines often compress filings, extensions, and final closes into one rounded number, but medtech deserves more discipline because the gap between capital raised and clinical validation is not fine print. It is the business.

CoreMap has raised meaningful capital before. The company announced a $10.5M Series A in 2020 and a $3M Series A milestone financing alongside a $20M Series B in 2022. Those rounds helped move the company from a scientific thesis toward a regulated clinical program.

The Problem CoreMap Is Trying to See

Atrial fibrillation is an irregular heart rhythm that can increase the risk of stroke, heart failure, and other cardiovascular complications. Catheter ablation can be effective, but persistent AF remains harder to treat because the electrical activity sustaining the arrhythmia can be complex, variable, and difficult to map with sufficient resolution.

CoreMap's thesis begins with measurement. The company says conventional approaches face two core limitations: poor spatial resolution and inadequate sample density. Its investigational platform combines proprietary microelectrodes, high-resolution signal capture, and mapping software intended to help electrophysiologists identify spatially constrained AF drivers and plan patient-specific ablation.

That is an important product boundary. CoreMap is not selling a commercially established cure, and the system remains investigational. The company is testing whether better visibility into the electrical behavior of persistent AF can support safer and more effective tailored treatment.

Why INvENI Matters

The INvENI study, ClinicalTrials.gov ID NCT06529978, is recruiting and sponsored by CoreMap. The global, multi-site, prospective feasibility study has an estimated enrollment of 245 participants and an estimated completion date of December 2026.

INvENI is structured across three phases. The program begins with high-fidelity endocardial electrogram collection and safety evaluation, then develops and evaluates a CoreMap-guided tailored ablation strategy, and ultimately compares the system's ability to identify AF drivers and guide therapy against a control approach. Primary effectiveness measures include freedom from documented recurrence of AF, atrial tachycardia, or atrial flutter throughout follow-up.

CoreMap received FDA Investigational Device Exemption approval in 2025 to expand the study into the United States. That milestone did not amount to commercial approval, but it allowed the company to gather U.S. clinical evidence under an FDA-authorized investigation.

The People Behind the Platform

CoreMap was founded in 2016 by Sarah Kalil, President and CEO, and Peter Spector, M.D., Chief Scientific Officer and Chair of the Board of Clinical and Scientific Advisors.

The leadership pairing fits the problem. Kalil brings a medical-device operating background, while Spector's academic and clinical work has focused on cardiac electrophysiology and the mechanisms underlying atrial fibrillation. The company's challenge is to convert that scientific foundation into a system that performs reliably across centers, operators, patients, and regulatory scrutiny.

The June 2026 filing also lists Gowri Raman, Adam Rothstein, and Allen Kamer as directors. It does not identify a current CTO, so no CTO is included in the publishing fields or social copy.

Why the Financing Matters

Clinical-stage medtech burns capital in ways that consumer software founders would find almost rude. Studies require sites, protocols, monitoring, data management, regulatory work, quality systems, manufacturing preparation, and teams that can keep all of those moving without letting enthusiasm outrun evidence.

The $35.51M equity sale gives CoreMap more capacity to execute through that expensive middle. Because the filing does not disclose a formal use of proceeds, assigning dollars to specific milestones would be speculative. The evidence-supported conclusion is that the financing strengthens the company's ability to continue the clinical and regulatory work already visible in INvENI.

For operators, the lesson is simple: capital is not the same as validation, but it can buy the runway required to earn validation. For investors, the bet is that improved mapping can make persistent AF ablation more precise and patient-specific in a field where outcomes still leave room for better tools.

What This Signals for Cardiac Electrophysiology

The competitive market includes established mapping and ablation platforms from major cardiovascular-device companies. CoreMap's opportunity is not size or distribution. It is a narrower scientific claim that higher-resolution mapping and better signal interpretation can reveal clinically useful AF drivers that existing workflows may miss.

That claim now faces the only test that matters: reproducible clinical evidence. If INvENI produces credible safety and effectiveness data, CoreMap could gain leverage in a market that values technologies capable of improving procedural decisions rather than simply adding another screen to the lab. If the data disappoints, no clever funding label will rescue the thesis.

The financing therefore marks progress, not arrival. CoreMap has put more capital behind a difficult measurement problem, aligned that work with a registered clinical study, and given its team additional room to let the evidence speak. In medtech, that is not a small achievement. It is simply the beginning of the expensive part.